1Freeman DJ,Norrje J.Caslake MJ,et al.C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study[J].Diabetes,2002,51(5):1596-1600.
3van Hecke MV,Dekker JM,Nijpels G,et al.Inflammation and endothelial dysfunction are associated with retinopathy:theHoorn Study[J].Diabetoloqia,2005,48(7):1300-1306.
1Weyer C, Yudkin JS, Stehouwer CD, et al. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis,2002,161:233-242.
2Daniel G, Hackam MD, Sonia S. Emerging risk factors for atherosclerotic vascular disease. JAMA, 2003,290: 932-939.
3Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 2002,105:1890-1896.
4Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med,2002,347,1557-1564.
5Keller KB, Lemberg L. Obesity and the metabolic syndrome. Am J Crit Care, 2003,12:167-170.
6Mortensen RF. C-reactive protein, inflammation, and innate immunity.Immunol Res, 2001,24:163-176.
7Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation,2000, 102:2165-2167.
8Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decrease eNOS expression and bioactivity in human aortic endothelial cells. Circulation, 2002,106:1439-1441.
9Festa AD, Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistanee syndrome. Circulation, 2000,102:42-47.
10Leinonen E, Hurt-Camejo E, Wiklund O, et al. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis, 2003,166: 384-394.
